Conventional stents versus stents loaded with 125iodine seeds for the treatment of unresectable oesophageal cancer: a multicentre, randomised phase 3 trial

Zhu, Hai-Dong; Guo, Jun; Mao, Aiwu; Lv, Wei‐Fu; Ji, Jiansong; Wang, Wenhui; Lv, Bin; Yang, Ruimin; Wu, Wei; Chen, Ni; Min, Jie; Zhu, Guangyu; Chen, Li; Zhu, Meiling; Dai, Zhenyu; Liu, Pengfei; Gu, Jianping; Ren, Wei; Shi, Ruihua; Xu, Ganggang; He, Shi-Cheng; Deng, Gang; Teng, Gao‐Jun

doi:10.1016/s1470-2045(14)70131-7

Cited by 135 publications

(100 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…114 Interestingly, a recent RCT of 160 patients indicated a longer median survival if the stent was loaded with radioactive seeds (177 versus 147 days, p=0.0046). 116 However, if chemotherapy is planned it often provides relief of dysphagia obviating the need for local treatment. Dysphagia may also be palliated by external radiotherapy.…”

Section: Local Treatmentmentioning

confidence: 99%

Oesophageal cancer

et al. 2017

View full text Add to dashboard Cite

SummaryOesophageal cancer is a clinically challenging disease requiring a multidisciplinary approach.The extensive treatment may be associated with serious limitations in health-related quality of life and yet still a poor prognosis. Recent decades have witnessed a gradual improvement in prognosis in many countries. Endoscopic procedures have increasingly been used in the treatment of premalignant and early oesophageal tumours. Neoadjuvant therapy with chemotherapy or chemoradiotherapy has supplemented surgery as standard treatment of locally advanced oesophageal cancer. Surgery has become more standardised and centralised. There are several therapeutic alternatives for palliative treatment. This review aims to provide insights into the current clinical management, on-going controversies and future needs in oesophageal cancer.3

show abstract

Section: Local Treatmentmentioning

confidence: 99%

Oesophageal cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…6,7 Esophageal cancer is the eighth most common cancer worldwide and the sixth leading cause of cancer-related mortality. 8 An estimated 456 000 new esophageal cancer cases (3% of all cancers) and 0.4 million cancer deaths (5% of all cancers) were recorded in 2012 worldwide. 9 The incidence rate of esophageal cancer, especially of adenocarcinoma, has increased significantly in recent years.…”

mentioning

confidence: 99%

GDF15 derived from both tumor-associated macrophages and esophageal squamous cell carcinomas contributes to tumor progression via Akt and Erk pathways

Urakawa

Utsunomiya

Nishio

et al. 2015

Laboratory Investigation

View full text Add to dashboard Cite

Tumor-associated macrophages (TAMs) are known to be involved in the progression, angiogenesis, and motility of various cancers. We previously reported the association between an increased number of infiltrating TAMs with tumor progression and poor prognosis in esophageal squamous cell carcinomas (ESCCs). To study the roles of TAMs in ESCC, we first exposed peripheral blood monocyte (PBMo)-derived macrophages from healthy volunteers to conditioned media of TE series human ESCC cell line (TECM) and confirmed the induction of the expression of the M2 macrophage marker CD204 and the protumorigenic factors interleukin (IL)-10, VEGFA, and MMPs. Next, we compared gene expression profiles between PBModerived macrophages stimulated with or without TECM by cDNA microarray and focused on growth differentiation factor 15 (GDF15) among the highly expressed genes including IL-6, IL-8, and CXCL1. Our immunohistochemical study of 70 surgically resected ESCCs revealed that GDF15 was present not only in cancer cells but also in macrophages. The high expression of GDF15 in the ESCCs was significantly correlated with several more malignant phenotypes including vessel invasion, lymph node metastasis, and clinical stages. Patients with high GDF15 expression showed significantly poorer disease-free survival (P = 0.011) and overall survival (P = 0.041). We also found that recombinant human GDF15 promotes cell proliferation and the phosphorylation of both Akt and Erk1/2 in ESCC cell lines in vitro. These results indicate that GDF15 is secreted by both TAMs and cancer cells in the tumor microenvironment and is associated with aberrant growth and a poor prognosis in human ESCC.

show abstract

“…While antireflux stents had a higher rate of AEs, they were minor and easily managed endoscopically. Other treatments such as brachytherapy, external radiotherapy or chemotherapy have also shown promising results in this situation 22 23 24 25 26 27 and should be further evaluated. Future research should focus on optimal treatment algorithms, including the otential association between endoscopic and non-endoscopic therapies.…”

Section: Discussionmentioning

confidence: 99%

Antireflux versus conventional self-expanding metallic Stents (SEMS) for distal esophageal cancer: results of a multicenter randomized trial

et al. 2016

View full text Add to dashboard Cite

License terms and the Société Française d'Endoscopie Digestive (SFED)Original article E730 THIEME Introduction ! Dysphagia is the most frequent symptom in patients presenting with an esophageal or gastric cardia cancer. Due to the late occurrence of symptoms, the goal of management in such cancers is focused on palliation in more than half of cases. In addition, the incidence of esophageal cancer is rising and the prognosis is poor with a 5-year overall survival rate less than 10 %, which emphasizes the importance of palliative treatments [1].Indeed, relief of dysphagia is a major issue in these situations, since it is responsible for poor quality of life, under nutrition, and performance status alteration [2,3]. Insertion of a self-expanding metal stent (SEMS) relieves malignant dysphagia and is associated with an improvement in patient' quality of life [4 -7]. Extension of adenocarcinoma of the distal esophagus frequently involves the gastro-esophageal junction. Therefore, deployment of SEMS in this location results in positioning the lower extremity of the stent in the stomach. While this position does not impair the efficacy of the stent in palliation of dysphagia, it has two major drawbacks: first, it increases the * These authors contributed equally.Coron E et al. Stents for distal esophageal cancer … Endoscopy International Open 2016; 04: E730-E736

show abstract

Conventional stents versus stents loaded with 125iodine seeds for the treatment of unresectable oesophageal cancer: a multicentre, randomised phase 3 trial

Cited by 135 publications

References 27 publications

Oesophageal cancer

Oesophageal cancer

GDF15 derived from both tumor-associated macrophages and esophageal squamous cell carcinomas contributes to tumor progression via Akt and Erk pathways

Antireflux versus conventional self-expanding metallic Stents (SEMS) for distal esophageal cancer: results of a multicenter randomized trial

Contact Info

Product

Resources

About